Mediators of Inflammation

Research Article

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Table 3

Combined treatment with etanercept and tacrolimus synergistically reduces the serum MMP-3 levels in hTNF-Tg mice.
VehicleETNTACETN+TAC
Serum MMP-3 level (ng/mL)
Serum MMP-1 level (ng/mL)
Serum MMP-9 level (ng/mL)
Etanercept (ETN; 4 mg/kg) was administered subcutaneously twice a week for 4 weeks. Tacrolimus (TAC; 3 mg/kg) was administered orally once daily for 4 weeks. The serum MMP-1, MMP-3, and MMP-9 levels were measured by ELISA. Data are representative of two independent experiments and presented as of five animals per group. compared with the vehicle group (Dunnett’s multiple comparison test). and compared with the tacrolimus-treated group (Student’s -test) and the etanercept-treated group (Aspin-Welch’s -test), respectively.